Letter to the editor
Flaws and weaknesses in estimating the budget impact of lung cancer screening in Spain
Defectos y debilidades en la estimación del impacto presupuestario de la detección del cáncer de pulmón en España
Antoni Rosella, Oriol Estradab, Francesc López-Seguíc, José Ángel Vicente-Gómezd, Natalia Robledinos-Antóne, Luis M. Seijof,g, Juan Carlos Trujillog,h,
a Barcelona Respiratory Network, Thorax Institute, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Germans Trias i Pujol Research Institute, Badalona, Barcelona, Spain
b Healthcare Strategy, Northern Metropolitan Territorial Management, Catalan Institute of Health, Barcelona, Spain
c Centre for Research in Health Economics, Pompeu Fabra University, Epidemiology and Evaluation Service, Hospital del Mar, Barcelona, Spain
d Germans Trias i Pujol Hospital, Catalan Institute of Health, Badalona, Barcelona, Spain
e Health Economics and Market Access Department, Johnson&Johnson, Madrid, Spain
f Neumology Department, Clínica Universidad de Navarra and CIBERES, Madrid, Spain
g CASSANDRA (Cancer Screening SmokingCessation & Respiratory Assessment) Project, Spain
h Thoracic Surgery Department, Hospital de la Santa Creu i Sant Pau and Hospital del Mar, Barcelona, Spain
